A protease inhibitor is a molecule that blocks proteases, the enzymes responsible for cutting proteins into smaller pieces. By jamming the machinery that viruses need to assemble new copies of themselves, protease inhibitors have become critical drugs in treating HIV, hepatitis C, and COVID-19. But protease inhibitors aren’t only pharmaceuticals. Your body produces its own, and they even show up naturally in foods like soybeans and lentils.
How Protease Inhibitors Work
Proteases are everywhere in biology. They make up 2 to 4 percent of all the proteins encoded in any organism’s genes, and they’re involved in digestion, blood clotting, immune defense, wound healing, and viral replication. Their job is to break the bonds between amino acids in a protein chain, essentially chopping proteins into functional pieces. A protease inhibitor prevents this chopping.
The most common approach is competitive inhibition: the inhibitor molecule slides into the protease’s active site (the groove where the cutting happens) and mimics the shape of the protein the enzyme normally targets. The protease grabs onto the inhibitor as if it were a real substrate, but the bond it tries to cut is either hydrolyzed extremely slowly or not at all, and no products are released. The enzyme stays locked up, unable to do its job.
Some inhibitors go further. A family called serpins uses a trap-and-destroy strategy. The serpin presents a bait loop to the protease, which clips it. But instead of releasing the cut pieces, the serpin undergoes a dramatic shape change that physically wrenches the protease to the opposite side of the molecule. This deforms the protease’s active site so completely that it can never function again. The process is entirely irreversible.
Small-molecule drug inhibitors can also be irreversible, using a reactive chemical group (sometimes called a “warhead”) that bonds directly to the catalytic machinery inside the enzyme. Others, like the COVID-19 drug nirmatrelvir, form a reversible covalent bond, temporarily locking the enzyme but releasing it over time, which is enough to halt viral replication when drug levels stay high.
Protease Inhibitors in HIV Treatment
HIV relies on a protease enzyme to cut long chains of viral protein into the smaller pieces needed to assemble new virus particles. Without this step, the virus produces immature, non-infectious copies that can’t spread to other cells. HIV protease inhibitors block that enzyme, and they’ve been a cornerstone of antiretroviral therapy since the mid-1990s.
The first HIV protease inhibitor, ritonavir, received FDA approval in March 1996. Others followed: atazanavir in 2003, fosamprenavir in 2003, tipranavir in 2005, and darunavir in 2006. Today these drugs are typically used in combination with other classes of antiretrovirals, a strategy that attacks the virus at multiple points in its life cycle and makes it far harder for resistance to develop.
Ritonavir plays a unique double role. Beyond its own antiviral activity, it’s widely used as a “booster” for other protease inhibitors. The liver enzyme CYP3A4 normally breaks down many of these drugs so quickly that they struggle to reach effective levels in the blood. Ritonavir irreversibly disables CYP3A4, meaning the enzyme stays nonfunctional until the body manufactures fresh copies. A low dose of ritonavir given alongside another protease inhibitor dramatically extends that drug’s time in the bloodstream, keeping it at therapeutic levels far longer than it could manage alone.
Treating Hepatitis C
Hepatitis C virus uses its own protease, called NS3/4A, to process the large viral proteins it needs for replication. Blocking NS3/4A was one of the breakthroughs in the shift toward direct-acting antiviral therapy, which replaced older interferon-based regimens that were less effective and far harder for patients to tolerate.
The latest generation of hepatitis C protease inhibitors, including glecaprevir and voxilaprevir, work across all major genotypes of the virus. Combined with a second antiviral that targets a different viral protein, these regimens cure more than 95 percent of patients regardless of whether their virus carried pre-existing resistance mutations. Glecaprevir (paired with pibrentasvir) was approved by the FDA in August 2017, and voxilaprevir (combined with sofosbuvir and velpatasvir) followed the same year. For most patients, treatment lasts 8 to 12 weeks.
Protease Inhibitors and COVID-19
The same boosting principle behind HIV treatment made the COVID-19 antiviral Paxlovid possible. Paxlovid pairs nirmatrelvir, which targets the SARS-CoV-2 main protease (called Mpro), with a low dose of ritonavir to keep nirmatrelvir circulating at effective levels.
The SARS-CoV-2 genome produces two large polyproteins that Mpro must cut at 11 specific sites to generate the nonstructural proteins the virus needs to replicate. Nirmatrelvir forms a reversible covalent bond with a key amino acid in the enzyme’s active site, then locks into place through a network of hydrogen bonds and hydrophobic interactions. With Mpro disabled, the virus can’t process its own proteins and replication stalls.
In the pivotal EPIC-HR trial of over 2,200 high-risk patients, Paxlovid reduced COVID-19 hospitalizations by 89 percent compared to placebo. Seven people in the placebo group died; none in the treatment group did. The FDA granted emergency use authorization in December 2021.
Protease Inhibitors Your Body Makes
Your cells produce their own protease inhibitors to keep enzymatic activity in check. Without them, proteases involved in inflammation, immune defense, and tissue remodeling could cause serious damage. Two examples found in nasal and skin tissue, cystatin A and SPINK5, help maintain the barrier function of epithelial cells. When these inhibitors are genetically deficient, the result can be conditions like atopic dermatitis or chronic sinus inflammation. Research on patients with eosinophilic chronic rhinosinusitis has shown significantly lower levels of both cystatin A and SPINK5 in their nasal tissue compared to healthy individuals.
Protease Inhibitors in Food
Legumes like soybeans, peas, lentils, and chickpeas contain a class of natural protease inhibitors called Bowman-Birk inhibitors. These small, tough proteins are remarkably resistant to digestion. They survive stomach acid and the enzymes of the small intestine, arriving in the large intestine in active form. Each Bowman-Birk inhibitor molecule can bind and deactivate two protease molecules simultaneously. Animal studies have shown that dietary Bowman-Birk inhibitors from multiple legume sources can suppress both inflammatory and carcinogenic processes in the gastrointestinal tract, making them a subject of ongoing interest as potential chemopreventive agents against colorectal cancer.
Side Effects of Long-Term Use
Protease inhibitors used in HIV treatment carry some notable metabolic side effects, particularly with long-term use. The most well-known is lipodystrophy, a pattern of fat redistribution where fat wastes away from the arms, legs, and face while accumulating around the abdomen and upper back. This happens because the drugs interfere with how fat cells process and store lipids.
HIV protease inhibitors also contribute to elevated cholesterol and triglyceride levels, and they can trigger insulin resistance by suppressing the activity of a glucose transporter in fat and muscle tissue called GLUT-4. Over time, this can increase the risk of developing diabetes. These metabolic effects have been a persistent challenge in HIV care, and they’re one reason newer antiretroviral regimens sometimes favor drug classes with fewer metabolic consequences when possible.